Cargando…

Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein

SARS-CoV-2 and SARS-CoV are genetically related coronavirus and share the same cellular receptor ACE2. By replacing the VSV glycoprotein with the spikes (S) of SARS-CoV-2 and SARS-CoV, we generated two replication-competent recombinant viruses, rVSV-SARS-CoV-2 and rVSV-SARS-CoV. Using wild-type and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongyue, Zhang, Yuhang, Li, Dong, Deng, Yong-Qiang, Xu, Hongde, Zhao, Chaoyue, Liu, Jiandong, Wen, Dan, Zhao, Jianguo, Li, Yongchun, Wu, Yong, Liu, Shujun, Liu, Jiankai, Hao, Junfeng, Yuan, Fei, Duo, Shuguang, Qin, Cheng-Feng, Zheng, Aihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578532/ https://www.ncbi.nlm.nih.gov/pubmed/34759261 http://dx.doi.org/10.1038/s41392-021-00797-9

Ejemplares similares

Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
por: Ding, Limin S., et al.
Publicado: (2022)

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus
por: Dong, Fangfang, et al.
Publicado: (2019)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

Insights from the Infection Cycle of VSV-ΔG-Spike Virus
por: Milrot, Elad, et al.
Publicado: (2022)

Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays
por: Li, Hongyue, et al.
Publicado: (2020)

Infection of SARS-CoV-2 causes severe pathological changes in mouse testis
por: Chen, Min, et al.
Publicado: (2023)

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023)

Antiviral Effect of pIFNLs against PEDV and VSV Infection in Different Cells
por: Chen, Jing, et al.
Publicado: (2022)

Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
por: Parham, Kate A., et al.
Publicado: (2023)

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV(MT)) in golden syrian hamster
por: Ke, Yong, et al.
Publicado: (2023)

Optimization of VSV‐ΔG‐spike production process with the Ambr15 system for a SARS‐COV‐2 vaccine
por: Rosen, Osnat, et al.
Publicado: (2022)

Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus
por: Lv, Lishan, et al.
Publicado: (2014)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2020)

Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography
por: Lerer, Elad, et al.
Publicado: (2021)

Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2
por: Taddeo, Adriano, et al.
Publicado: (2022)

Effectiveness of VSV vectored SARS-CoV-2 spike when administered through intranasal, intramuscular or a combination of both
por: Beitari, Saina, et al.
Publicado: (2023)

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures
por: Kiesslich, Sascha, et al.
Publicado: (2021)

SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus
por: Havranek, Katherine Elizabeth, et al.
Publicado: (2020)

Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
por: Makovitzki, Arik, et al.
Publicado: (2021)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
por: Gillespie, Paul F., et al.
Publicado: (2023)

Development and Applications of VSV Vectors Based on Cell Tropism
por: Tani, Hideki, et al.
Publicado: (2012)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Chimeric calicivirus-like particles elicit specific immune responses in pigs
por: Crisci, E., et al.
Publicado: (2012)

Structural prediction of chimeric immunogens to elicit targeted antibodies against betacoronaviruses
por: Simpson, Jamel, et al.
Publicado: (2023)

Distinct structural rearrangements of the VSV glycoprotein drive membrane fusion
por: Libersou, Sonia, et al.
Publicado: (2010)

Characterization of Monomeric Intermediates during VSV Glycoprotein Structural Transition
por: Albertini, Aurélie A., et al.
Publicado: (2012)

Evaluation of a replication-competent VSV-SIV vaccine candidate
por: Jurgens, CK, et al.
Publicado: (2012)

Cell- Cell Transmission of VSV-G Pseudotyped Lentivector Particles
por: Skinner, Amy M., et al.
Publicado: (2013)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
por: Bishnoi, Suman, et al.
Publicado: (2018)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

VSV based virotherapy in ovarian cancer: the past, the present and …future?
por: Orzechowska, Beata Urszula, et al.
Publicado: (2017)

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins
por: Chen, Jing, et al.
Publicado: (2022)

Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses
por: Ouyang, Maggie Jing, et al.
Publicado: (2023)

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
por: Martinez, David R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lq78ka0rr568qm5uivdichirvr